These results indicate that SEMA3F administration, either local or systemic, has similar anti-tumor and anti-angiogenic effects, by inhibiting the Akt-mTOR singling pathway (Nakayama et al., 2015a). This evidence concerns the gene AKT1 and neoplasm.